EDITORIAL SECTION
-
STRATEGY
Strategic Positioning for M&A
The biotechnology sector is characterised by a constant influx of small highly specialised companies
-
RESEARCH DEVELOPMENT
Cytiva Laboratory capsule filters
Our singleuse selfcontained filtration solutions help reduce contamination risk and lower manual handling
-
CLINICAL TRIALS
Virtual Clinical Trials
Virtual digital and decentralized are all descriptions of the novel ways that using technology changes
-
Bio Pharma
Biosimilars and Biobetters
Biosimilars are biologic medical products that are essentially identical to an original product manufactured
-
MANUFACTURING
Transformative Convergence of AI in Pharmaceutical Manufacturing
The pharmaceutical manufacturing industry is on the cusp of a revolutionary transformation driven by
-
Information Technology
Transformative Impact of Artificial Intelligence on Clinical Trials
Artificial Intelligence AI has rapidly evolved from a futuristic concept to a transformative tool across various industries
-
EXPERT Talk
From Clinical Trials to Pharmacovigilance: A Multi-Agent Future
The industry has automated within silos not across them Your clinical data management systems dont communicate with safety databases Trial monitoring...
Advisory Board
.webp "Juris Hmelnickis")
.webp "Eiman Shafa")
KNOWLEDGE BANK
-
Articles
Forgotten Biology: The Missing Link Behind Trial Outcomes
Clinical trials are often described as the science of uncertainty and that uncertainty is expected It is how evidence is built However not all uncertainty is scientific In many cases it arises when the biological context of an intervention is not carried through into the study population
-
Techno Trends
FORE Biotherapeutics Receives FDA Breakthrough Therapy Designation for Plixorafenib in Brain Cancer
FORE Biotherapeutics has received Breakthrough Therapy Designation from the US Food and Drug Administration FDA for its investigational drug plixorafenib developed for the treatment of adult patients with BRAF VEmutated highgrade glioma a severe form of brain cancer
-
Projects
Cambrex Announces $150 Million Expansion across U.S. and European Facilities
Cambrex has revealed significant progress on its expansion initiatives across the United States and Europe These projects are designed to boost capacity for manufacturing complex drugs
-
Research Insights
Interpretable multivariate survival models: Improving predictions for conversion from mild cognitive impairment to Alzheimer’s disease via data fusion and machine learning
Accurately predicting which individuals with mild cognitive impairment MCI will progress to Alzheimers disease AD can improve patient care This study examines the role of quantitative MRI qMRI cognitive evaluations
-
White Papers
Accelerating In-Vitro Antibody Discovery with Artificial Intelligence
Antibodies have transformed modern medicine reshaping treatment paradigms across autoimmune disorders oncology and infectious diseases As one of the most versatile and successful therapeutic modalities
TOP ARTICLES
-
1
How U.S. Drug Pricing and Tariffs Are Reshaping Big Pharma Profits in 2025
No Author
This article discusses the role of U.S. drug pricing reforms in 2025 and new pharmaceutical tariffs in transforming the profitability of Big Pharma. Although the reforms are intended to make the medic...
-
2
Curcumin’s Role as an Anti-Neurofibrillary Agent Towards Alzheimer's Disease
Sabrina Ruoyao Chen Zhang
Ronny Priefer
Alzheimer’s disease is a progressive neurodegenerative disease that afflicts millions of people globally. Symptoms typically present as memory loss and cognitive decline. Existing hypthoses focu...
-
3
Importance of Advanced Analytical Tools - Nitrosamines in Pharmaceutical Drug Substances and Drug Products
Bhaskar Vallamkonda
Nitrosamine impurities pose carcinogenic risks, prompting global regulatory concern. This review highlights recent advances in LC-MS/MS methods for detecting trace levels of nitrosamines, emphasizing...
-
4
Revolutionizing Healthcare: The Latest Innovations in Pharma Tech
Kate Williamson
In this article, the author discusses new tendencies of the pharmaceutical industry such as precision medicine, artificial intelligence in development of new drugs, wearable technology, 3D printing te...
-
5
How Telehealth Is Transforming Access to Care in Chronic Disease Management
Lesley Barton
For decades, the standard paradigm of chronic disease management has been reactive and episodic, anchored by intermittent, in-person consultations. This model leaves significant gaps in the continuum...
press releasesRead more...
Lysoway Therapeutics Announces Phase I Dosing of LW-1017, the First TRPML1 Agonist to Enter Clinical Development
Lysoway Therapeutics today announced that the first participant has been successfully dosed on May in the Companys Phase I clinical trial of LW a potent selective and highly brainpenetrant smallmolecule TRPML
ACROBiosystems Launches Global License Solution Upgrade for HEK293 Functional Cell Lines, Streamlining Compliance to Accelerate Biopharmaceutical R&D
ACROBiosystems announced a major upgrade to its global license solution for HEK functional cell lines Centered on customer value and empowering global biopharmaceutical innovation the upgrade simplifies
Harbour BioMed Announces U.S. FDA IND Clearance for HBM7004 for the Treatment of Advanced Solid Tumors
Harbour BioMed the Company HKEX a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology oncology and other disease
Repertoire Immune Medicines Announces FDA Fast Track Designation for its Investigational Immune Medicine, RPTR-1-201
Repertoire Immune Medicines a biotechnology company pioneering the discovery and development of programmable T celltargeted immune medicines today announced that the US Food and Drug Administration
Events Read more...
10 - 14
May 2026Respiratory Drug Delivery 2026
The Westin Kierland Phoenix, Arizona, USA
20 - 21
May 2026Pharmacovigilance Europe 2026
London, UK
20 - 22
May 2026PHARMA EURASIA 2026
Pharma & Med Tech Park, Tashkent, Uzbekistan
20 - 21
May 2026Pharma Partnering EU Summit 2026
Basel Marriott Hotel, Switzerland
21 - 22
May 2026Liver Diseases & Hepatology 2026
Paris, France
27 - 28
May 2026Future Labs Live 2026
Congress Center, Basel, Switzerland
27 - 28
May 2026UK Biotech Day 2026
Radisson Hotel & Conference Centre London Heathrow, UK
27 - 28
May 2026Digi-Tech Pharma & AI Conference
London, United Kingdom
LATEST NEWSRead more...
China grants breakthrough status to NHWD-870 for NUT carcinoma treatment
Chinas National Medical Products Administration NMPA has granted Breakthrough Therapy Designation to NHWD HCI an oral BET inhibitor developed by Zhejiang Wenda Pharmaceutical Technology Co Ltd
Halozyme and GSK Partner on Subcutaneous Oncology Treatments
Halozyme Therapeutics has entered into a global collaboration and licence agreement with GSK to develop subcutaneous formulations for several oncology therapies
Rznomics Receives FDA RMAT Status for Liver Cancer Therapy RZ-001
Rznomics announced that the US Food and Drug Administration has granted Regenerative Medicine Advanced Therapy RMAT designation to RZ the companys lead investigational treatment for hepatocellular carcinoma HCC
Apertura Gene Therapy and TSC Alliance Collaborate to Advance Gene Therapy for Tuberous Sclerosis Complex
Apertura Gene Therapy a biotechnology company focused on nextgeneration AAV capsids for gene delivery has entered into a collaboration with the TSC Alliance a nonprofit organisation dedicated to improving
Axsome's Auvelity Hits $8B Peak Sales Forecast Post-FDA Nod
Axsome Therapeutics anticipates peak sales of billion for its Auvelity drug after securing FDA approval for treating agitation in Alzheimers disease
Cellenkos Secures FDA Clearance to Begin CK0802 Trial in Steroid-Refractory GVHD
Cellenkos a clinicalstage biotechnology company focused on developing allogeneic tissuetargeted regulatory T cell Treg therapies has received clearance from the US Food and Drug Administration to proceed
